Valeant Pharmaceuticals Completes Acquisition of Coria Laboratories, Ltd.

ALISO VIEJO, Calif.--()--Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has completed its acquisition of Coria Laboratories, Ltd., a privately-held specialty pharmaceutical company focused on dermatology products in the United States. Under the terms of the agreement, Valeant purchased all of the outstanding shares of Coria from parent company, DFB Pharmaceuticals, Inc., and other shareholders for $95 million.

About Valeant

Valeant Pharmaceuticals International (NYSE:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

Contacts

Valeant Pharmaceuticals
Laurie W. Little, 949-461-6002

Contacts

Valeant Pharmaceuticals
Laurie W. Little, 949-461-6002